ViVita uses its patented SPEAR Process to strip immunological barriers from animal‑derived tissues, producing an immune‑compatible extracellular matrix called the BARE Patch. This biomaterial serves as a scaffold that guides the body’s own cells to regenerate functional tissue, enabling off‑the‑shelf replacements for organs and tissues without the need for long‑term medication or repeat transplants. The platform targets a broad range of xenogeneic tissue‑engineered products for regenerative medicine.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients requiring tissue or organ replacement often face limited donor availability, the need for lifelong immunosuppressive medication, and the risk of transplant rejection, leading to repeated surgeries and high mortality.
Solution
ViVita employs its patented SPEAR Process to strip immunogenic components from animal-derived extracellular matrix, creating the BARE Patch—a biomaterial that is immune-compatible with human patients. The BARE Patch serves as a structural scaffold that guides the body’s own cells to regenerate functional tissue, eliminating the need for chronic immunosuppression and repeat transplants. By producing off‑the‑shelf xenogeneic tissue and organ replacements, ViVita aims to provide durable, curative solutions for a range of clinical indications in regenerative medicine.
Target Audience
Primary customers are hospitals, transplant centers, and specialty surgeons seeking ready-to-use tissue and organ replacement products for patients with unmet regenerative needs.
Features
- SPEAR Process that removes immunological barriers while preserving native extracellular matrix architecture
- Immune‑compatible BARE Patch that integrates with host tissue and promotes endogenous regeneration
- Off‑the‑shelf manufacturing enables rapid availability without donor matching
- Scalable platform applicable to multiple tissue and organ types
- Regulatory‑compliant xenogeneic biomaterial derived from animal sources